Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
295M
-
Number of holders
-
127
-
Total 13F shares, excl. options
-
100M
-
Shares change
-
+14.5M
-
Total reported value, excl. options
-
$67.3M
-
Value change
-
+$9.87M
-
Put/Call ratio
-
1.85
-
Number of buys
-
46
-
Number of sells
-
-64
-
Price
-
$0.67
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q1 2024
146 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q1 2024.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 127 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 100M shares
of 295M outstanding shares and own 34.08% of the company stock.
Largest 10 shareholders include WASATCH ADVISORS LP (20.1M shares), ARMISTICE CAPITAL, LLC (17M shares), BlackRock Inc. (13.3M shares), VANGUARD GROUP INC (12.2M shares), ACADIAN ASSET MANAGEMENT LLC (4.94M shares), GEODE CAPITAL MANAGEMENT, LLC (3.36M shares), D. E. Shaw & Co., Inc. (3.07M shares), STATE STREET CORP (2.75M shares), RENAISSANCE TECHNOLOGIES LLC (2.6M shares), and TWO SIGMA ADVISERS, LP (1.43M shares).
This table shows the top 127 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.